Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Apalutamide by Johnson & Johnson for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Apalutamide is under clinical development by Johnson & Johnson and currently in Phase III for Metastatic Castration-Resistant Prostate Cancer (mCRPC)....
Data Insights
Apalutamide by Johnson & Johnson for Salivary Gland Cancer: Likelihood of Approval
Apalutamide is under clinical development by Johnson & Johnson and currently in Phase II for Salivary Gland Cancer. According to...